Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech Inc has demonstrated significant growth, with sales of surgical soft tissue repair products increasing by 24% year-over-year to $23.4 million, largely attributed to heightened demand for its CellerateRX Surgical Activated Collagen. Additionally, the company has seen a positive trend in its revenue for bone fusion products, which rose by 25% year-over-year to $3.1 million, indicating a robust performance across its product lines. Moreover, Sanara's strategy to expand its distribution network and penetrate additional healthcare facilities is poised to further enhance topline growth, positioning the company favorably within the medical technology sector.

Bears say

Sanara MedTech Inc reported net revenue of $26.3 million, which constitutes a year-over-year growth of 21.5%, yet this figure fell short of the projected $26.7 million. The company faces significant risks, including the potential for lower-than-expected revenue growth, challenges in customer acquisition, difficulties in launching new products and services, and the concern of dilution risk. Furthermore, a reassessment of the company's valuation led to a decrease in the EV/Revenue multiple from 4.3x to 3.0x, reflecting a negative sentiment regarding its future financial performance.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.